Abbott Laboratories
ABT
$132.58
$3.222.49%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.37% | 3.95% | 7.16% | 4.85% | 4.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.37% | 3.95% | 7.16% | 4.85% | 4.00% |
| Cost of Revenue | 5.45% | -0.18% | 10.44% | 2.02% | 2.68% |
| Gross Profit | 8.90% | 7.31% | 4.58% | 7.20% | 5.08% |
| SG&A Expenses | 5.29% | 2.79% | 8.16% | 6.11% | 7.37% |
| Depreciation & Amortization | -10.83% | -11.02% | -3.33% | -5.24% | -5.42% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.38% | 0.45% | 10.35% | 3.19% | 3.23% |
| Operating Income | 21.57% | 23.45% | -4.90% | 12.72% | 7.81% |
| Income Before Tax | 33.79% | 23.82% | 13.09% | 16.10% | -1.77% |
| Income Tax Expenses | 21.64% | 114.69% | -3,681.59% | 25.11% | 16.86% |
| Earnings from Continuing Operations | 36.64% | 8.16% | 478.98% | 14.62% | -5.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.64% | 8.16% | 478.98% | 14.62% | -5.31% |
| EBIT | 21.57% | 23.45% | -4.90% | 12.72% | 7.81% |
| EBITDA | 13.85% | 13.22% | -3.75% | 7.79% | 5.49% |
| EPS Basic | 36.60% | 8.23% | 479.67% | 14.56% | -4.16% |
| Normalized Basic EPS | 22.82% | 26.27% | -6.92% | 16.05% | 7.39% |
| EPS Diluted | 36.49% | 8.57% | 479.43% | 14.63% | -5.06% |
| Normalized Diluted EPS | 22.88% | 26.35% | -6.92% | 16.14% | 6.90% |
| Average Basic Shares Outstanding | 0.02% | -0.06% | -0.11% | 0.04% | -0.40% |
| Average Diluted Shares Outstanding | -0.02% | -0.14% | -0.11% | -0.04% | 0.07% |
| Dividend Per Share | 7.27% | 7.27% | 7.27% | 7.84% | 7.84% |
| Payout Ratio | -0.22% | -0.01% | -0.81% | -0.06% | 0.14% |